Dr. Reddy's Revenues Cross $2 Billion Milestone* in FY12
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) today announced its audited consolidated financial results for the quarter and full year ended March 31, 2012 under International Financial Reporting Standards (IFRS).
Consolidated revenues at Rs. 96.7 billion in FY12, year-on-year growth of 30%, driven by key markets of North America and Russia in Global Generics segment and Pharmaceutical Services and Active Ingredients segment.
Consolidated revenues of Rs. 26.6 billion in Q4 FY12, year-on-year growth of 32%.
EBITDA of Rs. 25.4 billion in FY12, 26% of revenues and recorded year-on-year growth of 51%.
EBITDA of Rs. 6.8 billion in Q4 FY12, 26% of revenues and recorded year-on-year growth of 34%.
Profit after Tax** in FY12 of Rs. 15.3 billion, year-on-year growth of 42%.
Profit after Tax** of Rs. 4.2 billion in Q4 FY12, year-on-year growth of 38%.
During the year, the company launched 141 new generic products, filed 88 new product registrations and filed 68 DMFs globally.
The Board of Directors of the Company has proposed a dividend of Rs. 13.75 (275%) per equity share of Rs. 5/- face value, subject to the approval of shareholders.
* Revenues based on the average billed dollar rate of 47.91
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.